Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Humacyte Inc (NQ: HUMA )

5.390 +0.340 (+6.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Humacyte Inc

< Previous 1 2 3 4 5 Next >
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Humacyte Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Humacyte, Inc. (HUMA)
From Kirby McInerney LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
(HUMA) - Analyzing Humacyte's Short Interest
Via Benzinga
How Is The Market Feeling About Humacyte?
Via Benzinga
How Is The Market Feeling About Humacyte?
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
InvestorNewsBreaks – EF Hutton Serves as Placement Agent to Humacyte Inc.’s (NASDAQ: HUMA) $30M RDO
Via Investor Brand Network
Kaplan Fox & Kilsheimer LLP is Investigating Humacyte, Inc. (HUMA) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Unpacking the Latest Options Trading Trends in Humacyte
Via Benzinga
(HUMA) - Analyzing Humacyte's Short Interest
Via Benzinga
Peering Into Humacyte's Recent Short Interest
Via Benzinga
Kaplan Fox &amp; Kilsheimer LLP is Investigating Humacyte, Inc. (HUMA) for Potential Securities Law Violations
NEW YORK - (NewMediaWire) - October 22, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). 
Via TheNewswire.com
Exposures Product Safety
Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox &amp; Kilsheimer LLP
NEW YORK - (NewMediaWire) - October 21, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). 
Via TheNewswire.com
Exposures Product Safety
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Kaplan Fox &amp; Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA)
NEW YORK, NY - (NewMediaWire) - October 19, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). 
Via TheNewswire.com
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
HUMA Stock Earnings: Humacyte Misses EPS for Q2 2024
HUMA stock results show that Humacyte missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To Review
FDA extends review timeline for Humacyte's FDA marketing application for its acellular tissue-engineered vessel in vascular trauma. Originally set for August 2024, the new action date remains... 
Via Benzinga
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today! 
Via InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%
Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 Bio at 101%. 
Via Benzinga
Three Small-Cap Stocks to Buy Before a September-Rate-Cut Rally
Discover three small-cap stocks to buy before the Fed acts on interest rates as these small-cap stocks will utilize any cuts to multiply. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
What's Going On With Huamacyte Shares Tuesday?
Humacyte has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement with Pluristyx and received Regenerative Medicine Advanced Therapy (RMAT)... 
Via Benzinga
Exposures Product Safety
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
From Pluristyx
Via Business Wire
Why Humacyte Stock Is Trading 15% Higher Monday
Humacyte received the Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for its Acellular Tissue Engineered Vessel. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.